Ossiam Boosts Stake in Johnson & Johnson (NYSE:JNJ)

Ossiam increased its position in Johnson & Johnson (NYSE:JNJ) by 1,480.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 371,276 shares of the company’s stock after buying an additional 347,786 shares during the period. Johnson & Johnson comprises approximately 0.9% of Ossiam’s holdings, making the stock its 26th largest position. Ossiam’s holdings in Johnson & Johnson were worth $58,194,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of JNJ. Natixis Investment Managers International boosted its holdings in shares of Johnson & Johnson by 0.6% during the 4th quarter. Natixis Investment Managers International now owns 126,900 shares of the company’s stock valued at $19,890,000 after purchasing an additional 790 shares during the last quarter. Personal CFO Solutions LLC boosted its holdings in shares of Johnson & Johnson by 0.8% during the 4th quarter. Personal CFO Solutions LLC now owns 14,779 shares of the company’s stock valued at $2,317,000 after purchasing an additional 113 shares during the last quarter. Sompo Asset Management Co. Ltd. boosted its holdings in shares of Johnson & Johnson by 18.1% during the 4th quarter. Sompo Asset Management Co. Ltd. now owns 62,143 shares of the company’s stock valued at $9,740,000 after purchasing an additional 9,530 shares during the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at about $44,000. Finally, Waterloo Capital L.P. lifted its holdings in shares of Johnson & Johnson by 169.3% in the 4th quarter. Waterloo Capital L.P. now owns 6,806 shares of the company’s stock valued at $1,067,000 after acquiring an additional 4,279 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on JNJ shares. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price target for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday, May 6th. The Goldman Sachs Group initiated coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price objective on the stock. Finally, Bank of America reduced their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Eight research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $174.07.

Johnson & Johnson Trading Up 0.5 %

Shares of NYSE:JNJ traded up $0.66 during trading on Friday, reaching $147.08. 5,111,626 shares of the company were exchanged, compared to its average volume of 7,280,428. The firm has a market capitalization of $353.97 billion, a PE ratio of 9.17, a P/E/G ratio of 2.43 and a beta of 0.53. The business’s fifty day simple moving average is $149.27 and its 200-day simple moving average is $154.88. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. Johnson & Johnson’s revenue was up 2.3% compared to the same quarter last year. During the same period last year, the company posted $2.68 earnings per share. On average, research analysts anticipate that Johnson & Johnson will post 10.63 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.37%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend was Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.